Clinical Trial News and Research

RSS

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Researchers in the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist and Texas Children's Hospital have found that a single dose of an otherwise harmless drug can safely control the severe and often lethal side effects associated with haploidentical stem cell transplantation.

15 May 2015

Patients with operable early-stage NSCLC could achieve better overall survival rates with SABR

Patients with operable stage I non-small cell lung cancer (NSCLC) could achieve better overall survival rates if treated with Stereotactic Ablative Radiotherapy (SABR) rather than the current standard of care -- invasive surgery -- according to research from a phase III randomized international study from The University of Texas MD Anderson Cancer Center.

15 May 2015

Researchers explore how low-level electrical stimulation reduces inflammation

The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, today released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine.

15 May 2015

Scientists identify new molecules that destroy cancer cells, save healthy ones

Researchers have identified new molecules that kill cancer cells while protecting healthy cells and that could be used to treat a variety of different cancers. The research shines a light on what happens to cells at the moment they become cancerous.

15 May 2015

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Argos is developing AGS-003, which is a fully personalized immunotherapy designed to induce a durable memory T-cell response specific to each patient’s cancer...

14 May 2015

Great Basin Scientific revenue up 31% in first quarter 2015

Great Basin Scientific, Inc., a molecular diagnostic testing company, today reported earnings results for the quarter ended March 31, 2015. Revenue for the quarter was $458,730, which represented a 31 percent increase in year-over-year revenues, and Loss from Operations was $3.9 million.

14 May 2015

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results and provided a business update for the first quarter ended March 31, 2015.

14 May 2015

TB Alliance announces start of clinical trial to treat XDR-TB

TB Alliance and its partners announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB). It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB.

14 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, today announced financial results for the three months ended March 31, 2015.

13 May 2015

Soligenix, Emergent BioSolutions sign development agreement

Soligenix, Inc., a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has initiated a development agreement with Emergent BioSolutions to implement a commercially viable, scalable production technology for the RiVax drug substance protein antigen.

13 May 2015

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic drug candidate INVAC-1.

13 May 2015

Researchers identify three genes involved in choroid plexus carcinoma

Researchers have identified three genes that play a pivotal role in the brain tumor choroid plexus carcinoma (CPC), a discovery that lays the groundwork for more effective treatment of this rare, often fatal cancer. St. Jude Children's Research Hospital scientists led the study, which appears today in the journal Cancer Cell.

12 May 2015

Experimental gene therapy holds promise against metastatic prostate cancer

Even with the best available treatments, the median survival of patients with metastatic, hormone-refractory prostate cancer is only two to three years. Driven by the need for more effective therapies for these patients, researchers at VCU Massey Cancer Center and the VCU Institute of Molecular Medicine have developed a unique approach that uses microscopic gas bubbles to deliver directly to the cancer a viral gene therapy in combination with an experimental drug that targets a specific gene driving the cancer's growth.

12 May 2015

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

Dana-Farber/Boston Children's Cancer and Blood Disorders Center has joined a clinical trial of immunotherapy for children with relapsed or treatment-resistant acute lymphoblastic leukemia (ALL). Led by Memorial Sloan Kettering Cancer Center, the trial is one of several nationally that are evaluating cancer immunotherapy, a treatment approach -- hailed by Science magazine as their Breakthrough of the Year in 2013 -- that triggers a patient's immune system to attack his or her cancer cells.

11 May 2015

WCG's New England IRB reaccredited by AAHRPP

WIRB-Copernicus Group, the world's largest provider of regulatory and ethical review services for human research and a leading provider of software solutions designed to accelerate clinical trials safely, announced today that its New England Institutional Review Board has been reaccredited by the Association for the Accreditation of Human Research Protection Programs.

11 May 2015

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Michael J. Fox Foundation for Parkinson's Research announces the acquisition of a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools — cell lines, plasmids, compounds and more — will accelerate biological study and drug development against this promising disease-modification target.

11 May 2015

The Project Data Sphere® initiative achieves 1st year milestones

Cancer community broadly shares, integrates, and analyzes clinical trial data within a single research platform to advance innovation and improve lives...

11 May 2015

Nevro Q1 revenue increases 45% to $9.7 million

Nevro Corp., a medical device company that has developed and commercialized an innovative, evidence-based neuromodulation platform for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2015.

11 May 2015

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Nevro Corp., a medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has received approval from the United States Food and Drug Administration for its Senza spinal cord stimulation (SCS) system.

10 May 2015

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Orexigen Therapeutics, Inc. today announced business and financial results for the first quarter ended March 31, 2015.

8 May 2015

Clinical Trial News and Research

Chemical drug safely controls side effects associated with haploidentical stem cell transplantation

Patients with operable early-stage NSCLC could achieve better overall survival rates with SABR

Researchers explore how low-level electrical stimulation reduces inflammation

Scientists identify new molecules that destroy cancer cells, save healthy ones

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Great Basin Scientific revenue up 31% in first quarter 2015

BrainStorm Cell Therapeutics reports financial results for Q1 2015, provides business update

TB Alliance announces start of clinical trial to treat XDR-TB

Galmed reports net loss of $2.5 million for first quarter 2015

Soligenix, Emergent BioSolutions sign development agreement

Invectys begins INVAC-1 phase I clinical trial in cancer patients

Researchers identify three genes involved in choroid plexus carcinoma

Experimental gene therapy holds promise against metastatic prostate cancer

Dana-Farber/Boston Children's joins immunotherapy clinical trial for children with ALL

WCG's New England IRB reaccredited by AAHRPP

MJFF announces acquisition of parkin research tools from Imago Pharmaceuticals

The Project Data Sphere® initiative achieves 1st year milestones

Nevro Q1 revenue increases 45% to $9.7 million

Nevro's Senza spinal cord stimulation system for delivering HF10 therapy gets FDA approval

Orexigen Therapeutics provides update on business and financial results for Q1 2015

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer